Oxygenta Pharmaceutical Ltd
Incorporated in 1990, Oxygenta Pharmaceutical Ltd manufactures Bulk Drugs and API including Pharmaceutical preparation, and Organic Fine Chemicals.
- Market Cap ₹ 222 Cr.
- Current Price ₹ 60.2
- High / Low ₹ 134 / 53.6
- Stock P/E
- Book Value ₹ -9.92
- Dividend Yield 0.00 %
- ROCE -24.9 %
- ROE %
- Face Value ₹ 10.0
Pros
- Company is expected to give good quarter
- Debtor days have improved from 68.2 to 17.0 days.
- Company's median sales growth is 27.9% of last 10 years
Cons
- Company has low interest coverage ratio.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2 | 6 | 12 | 8 | 13 | 21 | 14 | 52 | 61 | 31 | 40 | 109 | 112 | |
| 6 | 10 | 16 | 13 | 17 | 23 | 22 | 48 | 59 | 38 | 49 | 119 | 130 | |
| Operating Profit | -3 | -4 | -4 | -5 | -4 | -2 | -8 | 4 | 1 | -7 | -10 | -10 | -17 |
| OPM % | -142% | -67% | -34% | -59% | -31% | -10% | -57% | 7% | 2% | -23% | -24% | -9% | -16% |
| 0 | 0 | 0 | 1 | 1 | 0 | 4 | 2 | 1 | -1 | 0 | 1 | 0 | |
| Interest | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 2 | 2 | 4 |
| Depreciation | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 3 | 1 | 2 |
| Profit before tax | -4 | -7 | -6 | -6 | -4 | -3 | -6 | 3 | -0 | -11 | -14 | -12 | -23 |
| Tax % | 5% | -11% | 0% | 2% | 1% | -7% | -3% | 7% | 24% | 2% | -75% | -16% | |
| -4 | -6 | -6 | -6 | -5 | -3 | -6 | 3 | -1 | -12 | -3 | -10 | -17 | |
| EPS in Rs | -4.21 | -5.99 | -5.39 | -5.70 | -4.44 | -3.19 | -5.68 | 2.87 | -0.43 | -8.15 | -1.04 | -2.62 | -4.62 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 33% |
| 5 Years: | 51% |
| 3 Years: | 22% |
| TTM: | 142% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | -7% |
| 5 Years: | 1% |
| 3 Years: | % |
| TTM: | -9812% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 24% |
| 5 Years: | % |
| 3 Years: | 33% |
| 1 Year: | -33% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 14 | 14 | 33 | 37 | 37 |
| Reserves | -19 | -26 | -32 | -38 | -42 | -45 | -51 | -48 | -49 | -60 | -54 | -62 | -74 |
| 11 | 15 | 17 | 19 | 19 | 22 | 27 | 48 | 52 | 68 | 57 | 62 | 73 | |
| 17 | 19 | 24 | 27 | 30 | 34 | 33 | 24 | 14 | 32 | 26 | 46 | 81 | |
| Total Liabilities | 18 | 18 | 20 | 19 | 17 | 21 | 19 | 34 | 31 | 54 | 63 | 83 | 117 |
| 16 | 12 | 13 | 12 | 12 | 12 | 11 | 16 | 20 | 28 | 29 | 40 | 41 | |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2 | 6 | 7 | 6 | 5 | 9 | 7 | 17 | 11 | 26 | 34 | 44 | 75 | |
| Total Assets | 18 | 18 | 20 | 19 | 17 | 21 | 19 | 34 | 31 | 54 | 63 | 83 | 117 |
Cash Flows
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -3 | -4 | 1 | 1 | 1 | -8 | -3 | -2 | -2 | -2 | -13 | 3 | |
| -2 | 1 | -2 | -1 | -0 | -1 | -0 | -7 | -5 | -10 | -4 | -11 | |
| 4 | 3 | 1 | 0 | -1 | 8 | 3 | 9 | 6 | 11 | 17 | 9 | |
| Net Cash Flow | -1 | 0 | -0 | 0 | -0 | 0 | 0 | 0 | -0 | -0 | -0 | 0 |
Ratios
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 128 | 38 | 44 | 39 | 14 | 9 | 11 | 11 | 10 | 120 | 68 | 17 |
| Inventory Days | 33 | 84 | 41 | 122 | 57 | 121 | 100 | 121 | 56 | 178 | 149 | 78 |
| Days Payable | 10,165 | 1,800 | 667 | 599 | 396 | 203 | 190 | 137 | 50 | 362 | 249 | 113 |
| Cash Conversion Cycle | -10,004 | -1,678 | -582 | -439 | -325 | -73 | -79 | -5 | 16 | -64 | -32 | -18 |
| Working Capital Days | -1,576 | -616 | -454 | -512 | -438 | -164 | -275 | -14 | 8 | -94 | -89 | -184 |
| ROCE % | -188% | -1% | -47% | -42% | -25% |
Documents
Announcements
-
Intimation Under Regulation 30 The SEBI (LODR) Regulations, 2015, As Amended ('SEBI Listing Regulations') To Stock Exchanges Regarding Approval Of The Shareholders For Reclassification Of Person(S) Forming Part Of The Promoter/ Promoter Group From 'Promoter/ Promoter Group Category' To 'Public Category' Shareholder(S) Regulation 31A Of The SEBI Listing Regulations.
2d - Postal ballot approved reclassification of four promoters (942,700 shares, 2.55%) to public, effective Dec 11, 2025.
-
Shareholder Meeting / Postal Ballot-Scrutinizer"s Report
2d - Postal ballot approved reclassification to public; 99.98% votes in favour on December 11, 2025.
-
Minutes Of The Resolutions Passed By Way Of Postal Ballot
2d - 11 Dec 2025 postal ballot approved reclassification of four promoters holding 942,700 shares (2.55%).
-
Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot
2d - Members approved reclassification of certain promoters to public; postal ballot concluded Dec 11, 2025; 99.98% votes in favour.
- Announcement under Regulation 30 (LODR)-Newspaper Publication 12 Nov
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Products:[1]
Losartan potassium intermediate, Gabapentin intermediate, Antihypertensive drugs, Anti
cancer drugs, Antiulcer drugs, Antiretroviral drugs, Antihypertensive drugs, Antiviral drugs.